Testosterone replacement therapy is medical treatment for a diagnosed deficiency, not a course of steroids with a prescription. The difference is not moral, it is structural: a diagnosis confirmed by two morning blood tests, a dose that keeps levels inside the normal range, and monitoring that continues for as long as the treatment lasts.
This guide covers what the label requires, what the two largest trials actually measured, where fertility fits, and which numbers to track.
Key facts about TRT
| What it treats | Confirmed testosterone deficiency, with symptoms |
| Diagnosis requirement | Morning serum testosterone on at least two separate days, per the label |
| Common ester half-life | Testosterone cypionate intramuscularly about 8 days |
| Target | Mid normal range, symptom relief, stable levels |
| Duration | Open ended, with monitoring for as long as it continues |
| Main monitoring | Hematocrit, lipids, prostate, blood pressure, estradiol when symptoms appear |
Two tests exist because a single low morning value can be a bad night, not a diagnosis.
What TRT is and is not
Replacement means restoring a normal level, not exceeding it. The esters used for replacement sit in the injectable steroids category. The label frames treatment around confirmed hypogonadism and doses that bring serum testosterone into the normal range. A cycle is the opposite by design: supraphysiological doses for a fixed number of weeks, with the expectation that levels fall outside normal.
That single distinction drives everything else, from monitoring intervals to what happens to fertility.
How a diagnosis is confirmed
The label is explicit: before starting testosterone cypionate, the diagnosis is confirmed by measuring serum testosterone in the morning on at least two separate days, with values below the normal range, and by excluding other causes. That is not bureaucracy. Testosterone swings through the day and drops with poor sleep, illness and stress, so one low result proves very little.
Forms and half-lives
| Form | Typical interval | Practical note |
|---|---|---|
| Cypionate, intramuscular | Weekly or every 2 weeks | Half-life about 8 days, so long gaps produce visible peaks and troughs |
| Enanthate, intramuscular | Weekly or every 2 weeks | Very similar to cypionate in behaviour |
| Gel, transdermal | Daily | Steadier levels, transfer risk to others in the first hours |
| Subcutaneous, off label | Twice weekly or weekly | Smaller volumes, used by some clinics for smoother levels |
Whichever form is used, the goal is the same: a level that stays in range between doses. That is why a 2 week interval with cypionate is often changed to weekly when symptoms return before the next injection.
What the trials showed
Two large randomised trials dominate the modern discussion, and a 2026 review sums them up precisely.
| Trial | Population | What was found |
|---|---|---|
| Testosterone Trials (T Trials) | Men 65 and older with age related low testosterone | Improved sexual function and mood. No improvement in physical function, vitality or cognitive function |
| TRAVERSE | Men 45 to 80 at high cardiovascular risk | Non inferior to placebo for major adverse cardiovascular events. Prostate related events comparable. Fracture rates were unexpectedly higher in the testosterone group |
Risks and what to monitor
| Marker | Why it is checked | Frequency |
|---|---|---|
| Hematocrit and hemoglobin | The label advises periodic checks for polycythemia in long term androgen use | Baseline, 3 to 6 months, then at least yearly |
| Lipids | Serum cholesterol may increase during androgen therapy, per the label | Baseline, then yearly |
| Prostate | Prostate related events were comparable in TRAVERSE, but monitoring remains standard | Per clinical guidance, PSA baseline and follow up |
| Blood pressure | Rises with fluid retention and hematocrit | Every visit |
| Estradiol | Rises as testosterone aromatises, relevant if nipple sensitivity or water retention appear | If symptoms appear |
| Bone | Fracture signal in TRAVERSE was unexpected and deserves attention | Discuss with a doctor, especially in older men |
Fertility and TRT
Exogenous testosterone suppresses luteinizing hormone and follicle stimulating hormone, which suppresses sperm production. This is the single most consequential difference between TRT and the alternatives: men who want children often need a different strategy, such as hCG or a SERM, rather than replacement.
TRT compared with a cycle
| TRT | Cycle | |
|---|---|---|
| Goal | Normal range, symptom relief | Supraphysiological levels, muscle gain |
| Dose | Replacement | Several times replacement |
| Duration | Open ended | Fixed weeks, then recovery |
| Monitoring | Structured, ongoing | Often minimal or absent |
| Fertility | Suppressed while on treatment | Suppressed, then recovery attempted |
What TRT does not fix
The T Trials are useful precisely because they measured things people assume testosterone will fix. In men 65 and older with age related low testosterone, treatment improved sexual function and mood. It did not improve physical function, vitality or cognitive function.
| Outcome | Result in the T Trials | Practical reading |
|---|---|---|
| Sexual function | Improved | The most reliable benefit in men with confirmed deficiency |
| Mood | Improved | Consistent with the sexual function result |
| Physical function | No improvement | Strength and walking speed did not change measurably |
| Vitality | No improvement | Energy as a symptom is harder to move than expected |
| Cognitive function | No improvement | Memory and processing speed were unchanged |
That is not an argument against treatment. It is an argument for measuring the right thing: if the reason for starting is a symptom the trials did not improve, the honest expectation is that it may not change.
Measuring levels correctly
Where and when you measure changes the number, and the label already sets one rule: morning samples. Two more matter on therapy.
| Point | What to do | Why |
|---|---|---|
| Time of day | Morning, before 10 if possible | Testosterone has a daily rhythm, and the label assumes morning values |
| Timing in the interval | Trough, just before the next injection | That is the lowest point, the one that explains returning symptoms |
| Same laboratory | Repeat at the same lab and assay | Reference ranges and assays differ between labs |
| Free testosterone | Check when total is borderline or SHBG is abnormal | Total can look acceptable while free is low, or the opposite |
These four rules prevent most of the confusion that leads people to change dose every few weeks: a level taken at the wrong time is not a result, it is noise.
Frequently Asked Questions
Where this fits on this site
Replacement sits at one end of a spectrum that includes Anavar and other orals at the other. For recovery after a course rather than treatment, start with post cycle therapy and Clomid for men. Testosterone products are listed in the injectable steroids category.
- DailyMed label, testosterone cypionate injection: confirmation of hypogonadism with morning levels on two separate days, half-life about eight days, hematocrit and cholesterol monitoring
- Key findings on the efficacy and safety of testosterone therapy from two large randomized trials, 2026. PMID 42800050
- Testosterone therapy after TRAVERSE: rethinking cardiovascular and prostate cancer safety, 2026. PMID 42723557
- PubChem compound summary for testosterone, CID 6013
Medical disclaimer. This article is informational and does not replace advice from a licensed physician. Testosterone is a controlled prescription medicine, and treatment decisions belong with a doctor who has seen your blood work.